Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia
International Journal of Molecular Sciences · 20.05.2025 · 26 (10) · 4900
DOI: 10.3390/ijms26104900 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 20.05.2025. Verfasst von Hwan Hee Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea. Hauptthemen laut MEDLINE: Killer Cells, Natural, Chemokine CCL2, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program of the National Research Foundation of Korea (NRF), Korean Ministry of Education, Science and Technology.
Abstract (Originalsprache)
Hypoxia, a low-oxygen state, is a common feature of solid tumors. MCP1 (CCL2) is a small cytokine that is closely related to hypoxia and has a positive effect on tumor development. Hypoxia causes resistance to various treatments for solid tumors and the evasion of cancer immune surveillance by lymphocytes. Natural killer (NK) cells are innate lymphocytes that play an important role in cancer development, particularly in the liver. First, it was found that the incubation of HCC in hypoxia (2–5% O2) significantly increased the production of several inflammatory cytokines, including MCP1, compared to that of normal oxygen (20% O2). Subsequently, blocking MCP1 with an anti-MCP1 antibody in HCC cultures inhibited the growth and migration of HCC cells in vitro and in vivo. This was associated with a decrease in the expression of HIF-1α/STAT3 in HCC under hypoxia. Furthermore, blocking MCP1 in HCC cell cultures under hypoxia significantly increased the chemotaxis and activation of NK-92 cells against HCC cells. MCP1 blockade in HCC cell cultures under hypoxia induced a shift in NK cells to the CD56+dim population and an increase in the expression of the activation receptors NKG2D and NKp44. In conclusion, modulation of MCP1 could enhance NK activity against hypoxic HCC cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea.
- Duksung Innovative Drug Center, Duksung Women's University, Seoul 01369, Republic of Korea.
- Vessel-Organ Interaction Research Center, VOICE (MRC), Cancer Research Institute, College of Pharmacy, Kyungpook National University, Daegu 41566, Republic of Korea.
ORCID-Profile: Hyojeung Kang, Hyosun Cho
Förderung
- National Research Foundation of Korea
- Basic Science Research Program of the National Research Foundation of Korea (NRF)
- Korean Ministry of Education, Science and Technology
- Korean Government (MSIT)
Zitieren
APA
Lee, H. H., Kim, J., Park, E., Kang, H., & Cho, H. (2025). Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia. International Journal of Molecular Sciences, 26(10), 4900. https://doi.org/10.3390/ijms26104900
Vancouver
Lee HH, Kim J, Park E, Kang H, Cho H. Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia. International Journal of Molecular Sciences. 2025;26(10):4900. doi:10.3390/ijms26104900
BibTeX
@article{Lee2025,
author = {Lee, Hwan Hee and Kim, Juhui and Park, Eunbi and Kang, Hyojeung and Cho, Hyosun},
title = {Inhibition of MCP1 (CCL2) Enhances Antitumor Activity of NK Cells Against HCC Cells Under Hypoxia},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {10},
pages = {4900},
doi = {10.3390/ijms26104900}
}
EUVIMED